Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Monograph from the Acute Leukemia Forum 1999 on Advances and Controversies in the Therapy of Acute Myelogenous Leukemia
  • Published:

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

Leukemia volume 14, pages 474–475 (2000)Cite this article

Abstract

There are several competing models of stem cell involvement in acute myeloid leukemia (AML). At issue is whether the disease origin is in the pluripotent stem cell or whether it arises later in a more mature progenitor cell. The observation that the CD33 antigen is present on AML cells, and on normal and leukemic progenitors, suggested that one might be able to target these cells while sparing the normal stem cells. Response rates of acute myelogenous leukemia patients treated with the newly developed anti-CD33 antibody-calicheamicin conjugate suggest that at least for a proportion of patients early precursors responsible for re-establishing hematopoiesis are likely to be predominantly normal in origin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bernstein ID, Singer JW, Smith FO et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia Blood 1992 79: 1811–1816

    CAS  PubMed  Google Scholar 

  2. Singer JW, Bernstein ID, Davis PC, Walters TR, Raskind WH, Fialkow PJ . The effect of long-term marrow culture on the origin of colony-forming cells in acute myeloblastic leukemia: studies of two patients heterozygous for glucose-6-phosphate dehydrogenase Leukemia 1988 2: 148–152

    CAS  PubMed  Google Scholar 

  3. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R . Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia New Engl J Med 1987 317: 468–473

    Article  CAS  Google Scholar 

  4. Fialkow PJ, Jacobson RJ, Singer JW, Sacher RA, McGuffin RW, Neefe JR . Philadelphia chromosome (Ph1)-negative chronic myelogenous leukemia (CML): a clonal disease with origin in a multipotent stem cell Blood 1980 56: 70–73

    CAS  PubMed  Google Scholar 

  5. Anastasi J, Feng J, Dickstein JI et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia Leukemia 1996 10: 795–802

    CAS  PubMed  Google Scholar 

  6. Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nature Med 1997 3: 730–737

    Article  CAS  Google Scholar 

  7. Head DR . Revised classification of acute myeloid leukemia Leukemia 1996 10: 1826–1831

    CAS  PubMed  Google Scholar 

  8. Appelbaum FR, Matthews DC, Eary JF et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation priorto marrow transplantation for acute myelogenous leukemia Transplantation 1992 54: 829–833

    Article  CAS  Google Scholar 

  9. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678–3684

    CAS  PubMed  Google Scholar 

  10. Sievers E, Larson RA, Estey E, Stadtmauer EA, Roy D-CC, Spielberger R, Tarantolo S, Berger MS, Eten C, Manley L, Bernstein I, Appelbaum F . Preliminary results of the efficacy and safety of CMA-676 in patients with AML in first relapse Proc Am Soc Clin Oncol 1999 18: 7a (Abstr.)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA

    ID Bernstein

Authors
  1. ID Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernstein, I. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 14, 474–475 (2000). https://doi.org/10.1038/sj.leu.2401663

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401663

Keywords

This article is cited by

Search

Advanced search

Quick links